Advances in genetic testing for alzheimer's disease

Reviews in Neurological Diseases

Volumn 6, Issue 1, 2009, Pages 26-32

  Howard, Katherine L ^a   Filley, Christopher M ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Dementia; Genetic counseling; Genetic testing

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; PRESENILIN 1; PRESENILIN 2;

ALZHEIMER DISEASE; DIAGNOSTIC TEST; GENE; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; PHYSICIAN; PREDICTOR VARIABLE; PREVALENCE; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; APOLIPOPROTEIN E4; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENETIC TECHNIQUES; HUMANS; MUTATION; PRESENILIN-1;

EID: 63849114920     PISSN: 15452913     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Hebert LE, Scherr P, Bienias J, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60:1119-1122.
2. Seshadri S, Beiser A, Kelly-Hayes M, et al. The lifetime risk of stroke: estimates from the Framingham Study. Stroke. 2006;37:345-350.
3. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the N1NCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
4. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991;82:239-259.
5. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathological assessment of Alzheimer's disease. Neurology. 1991;41:479-486.
6. Working Group. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's disease. Neurobiol Aging. 1997; 18(suppl 4):S1-S2.
7. Mirra SS. Neuropathological assessment of Alzheimer's disease: the experience of the consortium to establish a registry for Alzheimer's disease. Int Psychogeriatr. 1997;9(suppl 1): 263-268.
8. Gatz M, Reynolds CA, Fratiglioni L, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63: 168-174.
9. Bird TD, Sumi SM, Nemens EJ, et al. Phenorypic heterogeneity in familial Alzheimer's disease: a study of 24 kindreds. Ann Neurol. 1989;25:12-2S.
10. Campion D, Dumanchin C, Hannequin D, et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet. 1999;65: 664-670.
11. Rosenberg RN. The molecular and genetic basis of AD: the end of the beginning: the 2000 Wartenburg lecture. Neurology. 2000;54: 2045-2054.
12. Rogaeva EA, Fafel KC, Song YQ, et al. Screening for PS1 mutations in a referral-based series of AD cases: 21 novel mutations. Neurology. 2001; 57:621-625.
13. Bertram L, McQueen M, Mullin K, et al. The AlzGene Database. Alzheimer Research Forum. http://www.alzforum.org. Updated February 8, 2009. Accessed February 19, 2009.
14. Cruts M, Rademakers R. Alzheimer disease and frontotemporal dementia mutation database [database online], http://www.molgen.ua.ac.be/ ADMutations. Accessed February 3, 2009.
15. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921-923.
16. Poirier J, Davignon J, Bouthillier D, et al. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet. 1993;342:697-699.
17. Blacker D, Haines JL, Rodes L, et al. ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. Neurology. 1997;48:139-147.
18. Myers RH, Schaefer EJ, Wilson PW, et al. Apolipoprotein E element 4 association with dementia in a population-based study: the Framingham study. Neurology. 1996;46:673-677.
19. Saunders AM, Schmader K, Breitner JC, et al. Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet. 1993;342: 710-711.
20. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7:180-184.
21. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer disease. Statement on use of apolipoprotein E testing for Alzheimer disease. JAMA. 199S;274:1627-1629.
22. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991;349:704-706.
23. Suzuki N, Cheung TT, Cai XD, et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science. 1994;264:1336-1340.
24. Rovelet-Lecrux A, Hannequin D, Raux G, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet. 2006;38:24-26.
25. Sorbi S, Nacmias B, Forleo P, et al. Epistatic effect of APP717 mutation and apolipoprotein E genotype in familial Alzheimer's disease. Ann Neurol. 1995;38:124-127.
26. Raux G, Guyant-Maréchal L, Martin C, et al. Molecular diagnosis of autosomal dominant early onset Alzheimer's disease: an update. J Med Genet. 2005;42:793-795.
27. Schupf N, Kapell D, Nightingale B, et al. Specificity of the fivefold increase in AD in mothers of adults with Down syndrome. Neurology. 2001;57:979-984.
28. Sherrington R, Rogaev El, Liang Y, et al. Cloning of a novel gene bearing missense mutations in early familial Alzheimer disease. Nature. 1995;375:754-760.
29. JankowskyJL, Fadale DJ, Anderson J, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet. 2004; 13: 159-170.
30. Lendon CL, Martinez A, Behrens IM, et al. E280A PS-1 mutation causes Alzheimer's disease but age of onset is not modified by ApoE alleles. Hum Mutat. 1997;10:186-195.
31. Larner AJ, Doran M. Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene. J Neurol. 2006;253:139-158.
32. Larner AJ, Doran M. Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene. J Neurol. 2006;253:139-158.
33. Cruts M, van Duijn CM, Backhovens H, et al. Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. Hum Mot Genet. 1998;7:43-51.
34. Levy-Lahad E, Wijsman EM, Nemens E, et al. A familial Alzheimer's disease locus on chromosome 1. Science. 1995;269:970-973.
35. Rogacv El, Sherrington R, Rogaeva EA, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature. 1995;376:775-778.
36. Lao JI, Beyer K, Fernandez-Novoa L. A novel mutation in the predicted TM2 domain of the presenilin 2 gene in a Spanish patient with late- onset Alzheimer's disease. Neurogenetics. 1998; 1:293-296.
37. Cruts M, van Broeckhoven C. Presenilin mutations in Alzheimer's disease. Hum Mutat. 1998,11:183-190.
38. Wijsman EM, Daw EW, Yu X, et al. APOE and other loci affect age-at-onset in Alzheimer's disease families with PS2 mutation. Am J Med Genet B Neuropsychiatr Genet. 2005;132:14-20.
39. Bird TD, Levy-Lahad E, Poorkaj P, et al. Wide range in age of onset for chromosome 1-related familial Alzheimer's disease. Ann Neurol. 1996;40:932-936.
40. Williamson J, Goldman JS, Mayeux R. Genetic research and genetic testing in Alzheimer's disease: a view from the bridge. Nut Clin Pract Neurol. 2007;3:356-357.
41. Goldman J5, Hou CE. Early-onset Alzheimer disease: when is genetic testing appropriate? Alzheimer Ms Assoc Disord. 2004;18:65-67.
42. Goldman JS, Miller BL, Safar J, et al. When sporadic disease is not sporadic: the potential for genetic etiology. Arch Neurol. 2004;61:213-216.
43. Wragg M, Hutton M, Talbot C; for the Alzheimer's Disease Collaborative Group. Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer's disease. Lancet. 1996;347:509-512.
44. Guidelines for the molecular genetics predictive test in Huntington's disease. International Huntington Association (1HA) and the World Federation of Neurology (WFN) Research Group on Huntington's Chorea. Neurology. 1994;44: 1533-1536.
45. Almqvist EW, Bloch M, Brinkman R, et al. A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease. Am J Hum Genet. 1999;64: 1293-1304.
46. Steinbart EJ, Smith CO, Poorkaj P, et al. Impact of DNA testing for early-onset familial Alzheimer disease and frontotemporal dementia. Arch Neurol. 2001;58:1828-1831.
47. Tibben A. Predictive testing for Huntington's disease. Brain Res Bull. 2007;72:165-171.
48. Huggins M, Bloch M, Wiggins S, et al. Predictive testing for Huntington disease in Canada: adverse effects and unexpected results in those receiving a decreased risk. Am J Med Genet. 1992;42:508-515.
49. Wahlin TB, Lundin A, Backman L, et al. Reactions to predictive testing in Huntington disease: case reports of coping with a new genetic status. Am J Med Genet. 1997;73:356-365.
50. Verlinsky Y, Rechitsky S, Verlinsky O, et al. Preimplantation genetic diagnosis for early-onset Alzheimer disease caused by V717L mutation. JAMA. 2002;287:1018-1021.
51. American Society of Human Genetics Board of Directors, American College of Medical Genetics Board of Directors. Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Am J Hum Genet. 1995;57:1233-1241.
52. Silverman JM, Raiford K, Edland S, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part VI. Family history assessment: a multicenter study of first-degree relatives of Alzheimer's disease probands and nondemented spouse controls. Neurology. 1994;44:1253-1259.
53. Green RC, Cupples I.A, Go R, et al. Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA. 2002;287:329-336.